Skip to content
Disclosery

TRV GP V, LLC

Follow

13F filer, CIK 1990717, Boston, MA

TRV GP V, LLC reported $498,241,492 across 3 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-340725

Period
2026-06-30
Reported value
$498M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RAPPreduced-854,708-$35.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-340725, largest first. % of portfolio is the value over $498,241,492, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 7,135,233 shares; 2025Q1: 7,135,233 shares; 2025Q2: 7,135,233 shares; 2025Q3: 7,135,233 shares; 2025Q4: 7,135,233 shares; 2026Q1: 7,135,233 shares; 2026Q2: 6,280,525 shares 6,280,525$262M52.53%-854,708Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 6,215,591 shares; 2025Q1: 6,215,591 shares; 2025Q2: 6,215,591 shares; 2025Q3: 6,215,591 shares; 2025Q4: 6,215,591 shares; 2026Q1: 6,215,591 shares; 2026Q2: 6,215,591 shares 6,215,591$208M41.78%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 950,800 shares; 2025Q2: 950,800 shares; 2025Q3: 950,800 shares; 2025Q4: 950,800 shares; 2026Q1: 950,800 shares; 2026Q2: 950,800 shares 950,800$28.4M5.69%0Timeline

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-340725 base2026-08-10acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-340725 Quarter ended 2026-06-302026-08-10acceptance time not in the bulk data set
13F-HR 0001193125-26-212010 Quarter ended 2026-03-312026-05-07acceptance time not in the bulk data set
13F-HR 0001193125-26-051785 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0001193125-25-280200 Quarter ended 2025-09-302025-11-13acceptance time not in the bulk data set
13F-HR 0000950123-25-007373 Quarter ended 2025-06-302025-08-08acceptance time not in the bulk data set
13F-HR 0000950123-25-004485 Quarter ended 2025-03-312025-05-09acceptance time not in the bulk data set
13F-HR 0000950123-25-002037 Quarter ended 2024-12-312025-02-13acceptance time not in the bulk data set